166 related articles for article (PubMed ID: 11881908)
1. Breast and ovarian cancer screening practices in healthy women with a strong family history of breast or ovarian cancer.
Isaacs C; Peshkin BN; Schwartz M; Demarco TA; Main D; Lerman C
Breast Cancer Res Treat; 2002 Jan; 71(2):103-12. PubMed ID: 11881908
[TBL] [Abstract][Full Text] [Related]
2. Factors associated with the incompliance with mammogram screening among individuals with a family history of breast cancer or ovarian cancer.
Wu H; Zhu K; Jatoi I; Shah M; Shriver CD; Potter J
Breast Cancer Res Treat; 2007 Mar; 101(3):317-24. PubMed ID: 16821080
[TBL] [Abstract][Full Text] [Related]
3. Cancer screening and risk-reducing behaviors of women seeking genetic cancer risk assessment for breast and ovarian cancers.
MacDonald DJ; Sarna L; Uman GC; Grant M; Weitzel JN
Oncol Nurs Forum; 2006 Nov; 33(2):E27-35. PubMed ID: 16518435
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
5. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
6. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.
Lerman C; Narod S; Schulman K; Hughes C; Gomez-Caminero A; Bonney G; Gold K; Trock B; Main D; Lynch J; Fulmore C; Snyder C; Lemon SJ; Conway T; Tonin P; Lenoir G; Lynch H
JAMA; 1996 Jun; 275(24):1885-92. PubMed ID: 8648868
[TBL] [Abstract][Full Text] [Related]
7. Awareness and concern about ovarian cancer among women at risk because of a family history of breast or ovarian cancer.
Andersen MR; Bowen D; Yasui Y; McTiernan A
Am J Obstet Gynecol; 2003 Oct; 189(4 Suppl):S42-7. PubMed ID: 14586320
[TBL] [Abstract][Full Text] [Related]
8. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.
Moyer VA;
Ann Intern Med; 2014 Feb; 160(4):271-81. PubMed ID: 24366376
[TBL] [Abstract][Full Text] [Related]
9. Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group.
Vasen HF; Haites NE; Evans DG; Steel CM; Møller P; Hodgson S; Eccles D; Morrison P; Stoppa Lyonet D; Chang-Claude J; Caligo M
Eur J Cancer; 1998 Nov; 34(12):1922-6. PubMed ID: 10023316
[TBL] [Abstract][Full Text] [Related]
10. Hereditary susceptibility to breast cancer: significance of age of onset in family history and contribution of BRCA1 and BRCA2.
Frank TS; Deffenbaugh AM; Hulick M; Gumpper K
Dis Markers; 1999 Oct; 15(1-3):89-92. PubMed ID: 10595259
[TBL] [Abstract][Full Text] [Related]
11. Screening adherence in BRCA1/2 families is associated with primary physicians' behavior.
Tinley ST; Houfek J; Watson P; Wenzel L; Clark MB; Coughlin S; Lynch HT
Am J Med Genet A; 2004 Feb; 125A(1):5-11. PubMed ID: 14755459
[TBL] [Abstract][Full Text] [Related]
12. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
Martin AM; Blackwood MA; Antin-Ozerkis D; Shih HA; Calzone K; Colligon TA; Seal S; Collins N; Stratton MR; Weber BL; Nathanson KL
J Clin Oncol; 2001 Apr; 19(8):2247-53. PubMed ID: 11304778
[TBL] [Abstract][Full Text] [Related]
13. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.
Burke W; Daly M; Garber J; Botkin J; Kahn MJ; Lynch P; McTiernan A; Offit K; Perlman J; Petersen G; Thomson E; Varricchio C
JAMA; 1997 Mar; 277(12):997-1003. PubMed ID: 9091675
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with decisions about clinical BRCA1/2 testing.
Armstrong K; Calzone K; Stopfer J; Fitzgerald G; Coyne J; Weber B
Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1251-4. PubMed ID: 11097234
[TBL] [Abstract][Full Text] [Related]
15. Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing.
Schwartz MD; Kaufman E; Peshkin BN; Isaacs C; Hughes C; DeMarco T; Finch C; Lerman C
J Clin Oncol; 2003 Nov; 21(21):4034-41. PubMed ID: 14581427
[TBL] [Abstract][Full Text] [Related]
16. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.
Loman N; Johannsson O; Kristoffersson U; Olsson H; Borg A
J Natl Cancer Inst; 2001 Aug; 93(16):1215-23. PubMed ID: 11504767
[TBL] [Abstract][Full Text] [Related]
17. Risk management options elected by women after testing positive for a BRCA mutation.
Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
[TBL] [Abstract][Full Text] [Related]
18. Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations.
Singh J; Thota N; Singh S; Padhi S; Mohan P; Deshwal S; Sur S; Ghosh M; Agarwal A; Sarin R; Ahmed R; Almel S; Chakraborti B; Raina V; DadiReddy PK; Smruti BK; Rajappa S; Dodagoudar C; Aggarwal S; Singhal M; Joshi A; Kumar R; Kumar A; Mishra DK; Arora N; Karaba A; Sankaran S; Katragadda S; Ghosh A; Veeramachaneni V; Hariharan R; Mannan AU
Breast Cancer Res Treat; 2018 Jul; 170(1):189-196. PubMed ID: 29470806
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer.
Couch FJ; DeShano ML; Blackwood MA; Calzone K; Stopfer J; Campeau L; Ganguly A; Rebbeck T; Weber BL
N Engl J Med; 1997 May; 336(20):1409-15. PubMed ID: 9145677
[TBL] [Abstract][Full Text] [Related]
20. Adherence to the breast cancer surveillance program for women at risk for familial breast and ovarian cancer versus overscreening: a monocenter study in Germany.
Vetter L; Keller M; Bruckner T; Golatta M; Eismann S; Evers C; Dikow N; Sohn C; Heil J; Schott S
Breast Cancer Res Treat; 2016 Apr; 156(2):289-99. PubMed ID: 26960712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]